Max Planck Institute - Articles and news items

Stem Cells Supplement 2013

Stem Cells: In-depth focus 2013

Genomics, Issue 2 2013, Supplements / 17 April 2013 / Katharina Drews, James Adjaye, Annette Meeson, George E. Plopper

The promise held by induced pluripotent stem cells for research and regenerative medicine.
Workshop preview – Cell based assays for screening.
Cardiac stem cells.
Stem Cells Roundtable.

European PROSPECTS for proteomics and systems biology

Issue 6 2008, Past issues / 3 December 2008 /

In its Research Framework Programme 7 (2007-2013), the European Commission sets the focus in health research on bringing the huge high-throughput data collection efforts of earlier programmes to the systems level. The ultimate goal of systems biology is the integration of various types of experimental data into models that represent and simulate physiological cell function. To this end, information on gene and protein expression and its dynamics, protein localisation, modification states and activation, their interaction in larger supra-molecular complexes and functional roles need to be compiled from numerous sources and formats and brought into context using advanced computational tools.

Live cell high content screening in drug development

Issue 4 2008, Past issues / 2 August 2008 /

Cell-based assays are essential for drug discovery and development as they increase the quality of lead compounds due to their physiological relevance. Toxicological data can be gathered during the early phases of hit selection and verification, reducing costs and attrition rates during clinical trials.

Utilisation of secondary screening

Issue 3 2008, Past issues / 19 June 2008 /

European Pharmaceutical Review has brought together four individuals from different sides of the scientific palette to discuss current and future issues surrounding secondary screening and maximising its potential.

Academic contribution to high-content screening for functional and chemical genomics

Issue 4 2007 / 21 July 2007 / Kerstin Korn and Eberhard Krausz (Corresponding author), Head, HT-Technology Development Studio (TDS), Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG)

High-content screening (HCS) is defined as multiplexed functional screening based on imaging multiple markers (e.g. nuclei, mitochondria etc.) in the physiologic context of intact cells by extraction of multicolour fluorescence information1. It is based on a combination of advanced fluorescence-based reagents, modern liquid handling devices, automated imaging systems and data processing, as well as sophisticated image analysis software.

The handling and analysis of large scale high content screening data

Issue 3 2007 / 23 May 2007 / Karol Kozak and Benjamin Eshun, Data Handling in TDS, Max Planck Institute of MolecularCell Biology and Genetics, Germany. Jeff Oegema, CEO, Scionics Computer Innovation, GmbH

Data management has become one of the central issues in High Content Screening (HCS) as it has high potential within predictive toxicity assessments. In particular, HCS applying automated microscopy requires a technology and system which is capable of storing and analying vast amounts of image and numeric data. HCS data includes comprehensive information about the bioactive molecules, the targeted genes and images, as well as their extracted data matrices after acquisition. Here we describe a bioinformatics solution HCS LIMS (Laboratory Information Management System) for the management of data from different screening microscopes. Additionally, the data handling approaches used in HCS for image converting, compression and archiving of images are discussed.

The right approach to human therapy

Issue 5 2006, Past issues / 28 September 2006 / Dr Simone Hess, Max-Planck-Institute for Infection Biology

The RIGHT (RNA Interference Technology as Human Therapeutic Tool) consortium consists of 18 research institutions and four companies from nine European countries. The project has been funded as an integrated project by the European Commission’s Sixth Framework Programme for Research and Development (FP6) since January 2005. Thomas F. Meyer from the Max Planck Institute for Infection Biology in Berlin is coordinating this European research project that aims at exploiting the vast potential of RNA interference (RNAi) for human therapy.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...